Table 1.
Baseline Characteristics of Study Subjects
| Characteristics | Total (n=426) | Treatment-naïve (n=184) | Treatment-experienced (n=242) | p-value |
|---|---|---|---|---|
| Age, yr | 48.4±11.8 | 46.9±12.4 | 49.5±11.2 | 0.03 |
| Male sex | 283 (66.4) | 112 (60.9) | 171 (70.7) | 0.04 |
| BMI, kg/m2 | 23.6±3.1 | 23.6±3.4 | 23.6±2.8 | 0.99 |
| Alcohol intake | 139 (32.7) | 69 (37.5) | 70 (29.0) | 0.07 |
| DM | 23 (5.4) | 14 (7.6) | 9 (3.7) | 0.13 |
| Cirrhosis | 134 (31.5) | 73 (39.7) | 61 (25.2) | 0.002 |
| ALT, IU/L | 110.3±323.4 | 188.1±470.1 | 51.1±92.0 | <0.001 |
| Creatinine, mg/dL | 0.8±0.2 | 0.7±0.2 | 0.8±0.2 | 0.06 |
| eGFR, mL/min/1.73 m2 | 103.4±14.1 | 105.0±15.3 | 102.2±13.0 | 0.05 |
| HBeAg-positive | 287 (68.0) | 105 (57.1) | 182 (76.5) | <0.001 |
| HBV DNA, log10IU/mL | 4.8±2.2 | 6.2±1.7 | 3.8±1.8 | <0.001 |
| HBV DNA ≥8 logIU/mL | 51 (12.0) | 43 (23.4) | 8 (3.3) | <0.001 |
| TDF therapy | <0.001 | |||
| TDF monotherapy | 351 (82.4) | 184 (100.0) | 167 (69.0) | |
| TDF combination therapy* | 75 (17.6) | 0 | 75 (31.0) | |
| Previous NA resistant mutations† | - | - | - | |
| LAM-R | 143 (91.7) | |||
| ADV-R | 25 (16.0) | |||
| ETV-R | 30 (19.2) | |||
| MDR | 43 (17.8) | |||
| Follow-up duration, mo | 28.4 (12–36) | 25.8 (12–36) | 30.4 (12–36) | <0.001 |
Data are presented as mean±SD, number (%), or median (range).
BMI, body mass index; DM, diabetes mellitus; ALT, alanine aminotransferase; eGFR, estimated glomerular filtration rate; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; TDF, tenofovir disoproxil fumarate; NAs, nucleos(t)ide analogues; LAM-R, lamivudine resistance; ADV-R, adefovir-resistance; ETV-R, entecavir-resistance; MDR, multidrug resistance.
*
TDF combined with other NAs;
†
LAM-R mutations include rtM204V/I±rtL180M, ADV-R mutations include rtA181T/V and rtN236T/V, and ETV-R mutations include rtT184, rtI169, and rtS202.